Home > Insider Trading > Filing (0001077183-25-000090)

Filing Details

Accession Number:: 0001077183-25-000090
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-05-06 16:08:57
Reporting Period:: 2025-05-02

Filing Date:: 2025-05-06
Accepted Time:: 2025-05-06 16:08:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1077183	Neogenomics Inc	NEO	Services-Testing Laboratories (8734)	742897368

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1463145	Scott Jeffrey Sherman	9490 Neogenomics Way Fort Myers FL 33912	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-05-02	20,000	$7.51	158,494	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right to Buy)	$11.62		2029-12-05	249,169	249,169	Direct
Common Stock	Stock Option (Right to Buy)	$19.65		2030-05-11	73,016	73,016	Direct
Common Stock	Restricted Stock Unit	$0.00			26,011	26,011	Direct
Common Stock	Performance Stock Unit	$0.00	2026-05-11		39,016	39,016	Direct
Common Stock	Stock Option (Right to Buy)	$16.45		2034-02-23	77,913	77,913	Direct
Common Stock	Performance Stock Unit	$0.00	2027-02-23		46,606	46,606	Direct
Common Stock	Restricted Stock Unit	$0.00	2026-04-13		59,382	59,382	Direct
Common Stock	Restricted Stock Unit	$0.00			31,071	31,071	Direct
Common Stock	Stock Option (Right to Buy)	$13.05		2035-02-21	214,900	214,900	Direct
Common Stock	Restricted Stock Unit	$0.00			126,476	126,476	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2029-12-05	249,169	249,169	Direct
2030-05-11	73,016	73,016	Direct
	26,011	26,011	Direct
	39,016	39,016	Direct
2034-02-23	77,913	77,913	Direct
	46,606	46,606	Direct
	59,382	59,382	Direct
	31,071	31,071	Direct
2035-02-21	214,900	214,900	Direct
	126,476	126,476	Direct

Footnotes

This balance includes 1,430 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.
On December 5, 2022, Mr. Sherman was granted 249,169 stock options. The options vest ratably over four years with the first tranche vesting on December 7, 2023.
On May 11, 2023, Mr. Sherman was granted 73,016 stock options. The options vest ratably over the first three anniversary dates of the grant date.
On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Once vested, the shares of common stock are not subject to expiration.
On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
On February 23, 2024, Mr. Sherman was granted 77,913 stock options. The options vest ratably over the first three anniversary dates of the grant date.
On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company
On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
On February 21, 2025, Mr. Sherman was granted 214,900 stock options. The options vest ratably over the first three anniversary dates of the grant date.
On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.